CLINICAL TRIALS PROFILE FOR MIACALCIN

All Clinical Trials for MIACALCIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01652573 ↗	Calcitonin for Treating X-linked Hypophosphatemia	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	N/A	2011-03-01	X-linked hypophosphatemia (XLH) is the most common form of inherited rickets in the United States. It also causes bone disease in adults. XLH is caused by overproduction of a hormone call FGF23, which makes the body waste phosphate. This study is designed to determine if nasal calcitonin, an already approved drug in the US, can lower blood levels of FGF23 and reduce phosphate wasting in patients with XLH. In this study the investigators will: 1. Determine whether nasal calcitonin significantly lowers integrated 24-hour blood levels of FGF23 in patients with XLH. 2. Evaluate whether nasal calcitonin improves serum phosphate levels in XLH. 3. Assess whether nasal calcitonin improves blood levels of the active form of vitamin D and calcium absorption from the intestine. 4. Make sure that nasal calcitonin is safe and well tolerated.
NCT01652573 ↗	Calcitonin for Treating X-linked Hypophosphatemia	Completed	Yale University	N/A	2011-03-01	X-linked hypophosphatemia (XLH) is the most common form of inherited rickets in the United States. It also causes bone disease in adults. XLH is caused by overproduction of a hormone call FGF23, which makes the body waste phosphate. This study is designed to determine if nasal calcitonin, an already approved drug in the US, can lower blood levels of FGF23 and reduce phosphate wasting in patients with XLH. In this study the investigators will: 1. Determine whether nasal calcitonin significantly lowers integrated 24-hour blood levels of FGF23 in patients with XLH. 2. Evaluate whether nasal calcitonin improves serum phosphate levels in XLH. 3. Assess whether nasal calcitonin improves blood levels of the active form of vitamin D and calcium absorption from the intestine. 4. Make sure that nasal calcitonin is safe and well tolerated.
NCT03342001 ↗	Hypothyroidism Treated With Calcitonin	Completed	University of Maryland	Phase 4	2018-06-18	Some people with hypothyroidism have persistent symptoms despite adequate treatment with thyroid hormones. We are testing whether giving calcitonin to such people will improve their quality of life.
NCT03342001 ↗	Hypothyroidism Treated With Calcitonin	Completed	University of Maryland, Baltimore	Phase 4	2018-06-18	Some people with hypothyroidism have persistent symptoms despite adequate treatment with thyroid hormones. We are testing whether giving calcitonin to such people will improve their quality of life.
NCT03812991 ↗	The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries	Recruiting	University of Missouri-Columbia	Phase 4	2019-07-01	Pelvic ring fractures in the geriatric population are a rising problem for surgeons in industrialized countries. Many of these low-energy fractures are treated nonoperatively; however, pain is a significant factor in recovery of these patients and often inhibits their ability to mobilize. Most of these fractures are lateral compression type 1 injuries which are defined as an impaction to the sacrum with varying amounts of anterior/pubic root/rami fractures. Many of these patients in the geriatric population suffer from osteoporosis and the injuries are often sustained from a low-energy mechanism like a fall. The tenet of treatment for all osteoporotic fractures is early mobilization. It is well known that extended periods of bed rest will lead to pneumonia, decubitus ulceration, deep venous thrombosis, and, in the case of the pelvis, not prevent subsequent deformity. Calcitonin is a polypeptide containing 32 amino acids, and it plays a role in the regulation of bone metabolism as a hormone that prevents bone resorption. Intranasal salmon calcitonin (ISC) has been demonstrated to decrease pain and improve the level of activity in patients with acute vertebral osteoporotic compression fractures when administered within the first 5 days of onset of pain/injury. It has also demonstrated an immediate post analgesic effect in osteoporotic distal radius fractures treated nonoperatively. The antihyperalgesic action of calcitonin appears to be mediated by serotonin receptors. The purpose of this study is to evaluate the analgesic effect of ISC on geriatric patients with pelvic ring injuries who are treated nonoperatively.

Clinical Trial Conditions for MIACALCIN

Condition Name

Condition Name for MIACALCIN
Intervention	Trials
Hypercalcemia	1
Hypophosphatemic Rickets, X Linked Dominant	1
Hypothyroidism	1
Pelvic Ring Fractures	1

Condition MeSH

Condition MeSH for MIACALCIN
Intervention	Trials
Hypophosphatemia	1
Hyperparathyroidism, Primary	1
Familial Hypophosphatemic Rickets	1
Hyperparathyroidism	1

Clinical Trial Locations for MIACALCIN

Trials by Country

Trials by Country for MIACALCIN
Location	Trials
United States	4

Trials by US State

Trials by US State for MIACALCIN
Location	Trials
Ohio	1
Missouri	1
Maryland	1
Connecticut	1

Clinical Trial Progress for MIACALCIN

Clinical Trial Phase

Clinical Trial Phase for MIACALCIN
Clinical Trial Phase	Trials
Phase 4	3
N/A	1

Clinical Trial Status

Clinical Trial Status for MIACALCIN
Clinical Trial Phase	Trials
Completed	2
Recruiting	1
Unknown status	1

Clinical Trial Sponsors for MIACALCIN

Sponsor Name

Sponsor Name for MIACALCIN
Sponsor	Trials
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	1
Yale University	1
University of Maryland	1

Sponsor Type

Sponsor Type for MIACALCIN
Sponsor	Trials
Other	6
NIH	1